Ben Venue Laboratories, a member of the Boehringer Ingelheim Group, has signed an agreement to sell its Bedford Laboratories U.S. injectable generics business to Hikma Pharmaceuticals PLC. Bedford Laboratories had provided generic sterile injectable medicines in the U.S., with a focus on acute-care hospitals, group purchasing organizations and oncology treatment centers. Ben Venue had ceased all operations of its generic sterile injectables business by the end of 2013 due to product quality manu...